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Abstract
Background: Asthma management guidelines recommend a stepwise approach to instituting and adjusting anti-
inflammatory controller therapy for children with asthma. The objective of this retrospective observational study was 
to describe prescribing patterns of asthma controller therapies for children in a primary care setting.
Methods: Data from the UK General Practice Research Database were examined for children with recorded asthma or 
recurrent wheezing who, from September 2006 through February 2007, were ≤ 14 years old at the time of a first 
asthma controller prescription after ≥ 6 months without a controller prescription. We evaluated demographic 
characteristics, asthma duration, comorbidities, asthma-related health care resource use, and prescribed daily dose of 
controller medication. In addition, physicians for 635 randomly selected patients completed a survey retrospectively 
classifying asthma severity at the prescription date and describing therapy and health care utilization for 6 prior 
months.
Results: We identified 10,004 children, 5942 (59.4%) of them boys, of mean (SD) age of 8.0 (3.8) years. Asthma controller 
prescriptions were for inhaled corticosteroid (ICS) monotherapy for 9059 (90.6%) children; ICS plus long-acting β2-
agonist (LABA) for 698 (7.0%); leukotriene antagonist monotherapy for 91 (0.9%); ICS plus leukotriene antagonist for 55 
(0.6%); and other therapy for 101 (1.0%), including 45 (0.45%) children who were prescribed LABA as monotherapy. 
High doses of ICS (> 400 μg) were prescribed for 44/2140 (2.1%) children < 5 years old and for 420/7452 (5.6%) children 
≥ 5 years. Physicians reported asthma severity as intermittent for 346/635 (55%) patients and as mild, moderate, and 
severe persistent for 159 (25%), 71 (11%), and 11 (2%), respectively (severity data missing for 48 [8%]). The baseline 
characteristics and controller therapy prescriptions of the survey cohort were similar to those of the full cohort.
Conclusions: Physician classifications of asthma severity did not always correspond to guideline recommendations, as 
leukotriene receptor antagonists were rarely used and high-dose ICS or add-on LABA was prescribed even in 
intermittent and mild disease. In UK primary care, monotherapy with ICS is the most common controller therapy at all 
levels of asthma severity.
Background
Asthma usually begins in the first years of life and is the
most common chronic disease of childhood in developed
countries [1,2]. In the United Kingdom (UK) and other
developed countries there are some indications that the
incidence of childhood asthma may have peaked at the
end of the last century [2-4]. Nonetheless, a large propor-
tion of children are affected-an estimated 1 in 11 children
in the UK [5]-and asthma is a common condition usually
managed by general practitioners (GPs).
Anti-inflammatory therapy is the cornerstone of phar-
macotherapy for persistent asthma to counter the chronic
airway inflammation that characterises this condition.
International and British asthma management guidelines
recommend a stepwise approach to instituting and
adjusting daily controller (preventer) anti-inflammatory
therapy, beginning with the dose of inhaled corticosteroid
(ICS) appropriate to the severity of asthma [6-9]. For chil-
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dren 5 years and older with worsening symptoms, or as
necessary to achieve asthma control, options for control-
ler therapy include increasing the ICS dose or add-on
therapy with inhaled long-acting β2-agonist (LABA) or
leukotriene receptor antagonist (LTRA). For children
under 5, the British guidelines recommend an LTRA for
those who cannot use ICS and as the sole recommended
add-on therapy to ICS [6,7], and a recent consensus
report places greater emphasis on using LTRA as an
alternative to ICS at all ages [1]. Short-acting bronchodi-
lators are recommended for relief of mild intermittent
asthma and should always be available to treat asthma
symptoms as needed for children with persistent asthma
who are using regular controller therapy [6-9].
The objective of this cross-sectional study was to
describe prescribing patterns of asthma controller thera-
pies for children in the UK primary care setting who had
not received a controller therapy prescription in the prior
6 months and to explore the clinical and demographic
characteristics influencing the choice of medication pre-
scribed, as well as health care utilisation 6 months prior.
In addition, we describe these parameters for a sub-
cohort of children whose asthma severity at the time of
initiating controller therapy was assessed retrospectively.
Table 1 summarises the treatment recommendations for
childhood asthma that were current at the time of this
study [7,9]. These recommendations have remained little
changed since then [6,8].
Methods
Data source
Data regarding diagnosis, prescriptions, hospitalisations,
co-morbidities, and demographic and clinical character-
istics were derived from the General Practice Research
Database (GPRD). The GPRD [10] is a large computer-
ised database containing anonymised longitudinal medi-
cal records from approximately 500 primary care
practices throughout the UK (England, Scotland, North-
ern Ireland, and Wales). Well-accepted and validated for
respiratory epidemiologic research in primary care
[11,12], the GPRD contains records for over 13 million
patients; active records are available for 3.6 million
patients, equivalent to ~5.5% of the population of the UK.
Approval was given for the use of GPRD data for this
study by the UK Medicines and Healthcare products Reg-
ulatory Agency (MHRA) Independent Scientific Advi-
sory Committee.
Patients
We identified children who, from September 2006
through February 2007, were ≤ 14 years old at the time of
Table 1: Summary of treatment recommendations for childhood asthma according to 2005 Global Initiative for Asthma 
(GINA) guidelines  and 2005 British Thoracic Society (BTS) guidelines 
2005 GINA Guidelines for adults & children > 5 years old* 2005 BTS Guidelines for children 5-12 years old*
GINA Step 1 Intermittent 
asthma
No controller medication necessary 
Short acting β2 agonist as needed
BTS Step 1 Mild 
intermittent asthma
Short acting β2 agonist as 
required
GINA Step 2 Mild persistent 
asthma
Low-dose ICS (or SR-theophylline; 
cromone; or leukotriene modifier)
BTS Step 2 Regular 
preventer therapy
ICS 200-400 μg/d†: 200 μg/d is a 
reasonable starting dose [for 
those < 5 y, use LTRA if cannot 
use ICS]
GINA Step 3 Moderate 
persistent asthma
Low- to medium-dose ICS plus 
inhaled LABA (or medium-dose ICS 
plus SR-theophylline, plus oral LABA, 
or plus leukotriene modifier; OR 
high-dose ICS) [for those ≤ 5 y, 
medium-dose ICS]
BTS Step 3 Add-on 
therapy
Add inhaled LABA; if poor 
response try ICS 400 μg/d; if poor 
response, add LTRA or SR-
theophylline (ICS dose up to 400 
μg/d) [for those 2-5 y, trial of 
LTRA]
GINA Step 4 Severe persistent 
asthma
High-dose ICS plus LABA plus 1 or 
more of the following if needed: SR-
theophylline, leukotriene modifier, 
oral LABA, oral steroid, anti-IgE [for 
those ≤ 5 y, high-dose ICS plus add-
on Rx if needed]
BTS Step 4 Persistent 
poor control
Increase ICS dose to 800 μg/d 
Consider adding the following if 
needed: LTRA, theophylline, SR-
β2 agonist tablets [for those < 5 y, 
refer to respiratory paediatrician]
-- -- BTS Step 5 
Continuous or 
frequent use of oral 
steroids
Use daily steroid tablet in lowest 
dose; maintain high-dose ICS; 
refer to respiratory paediatrician
ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; LTRA = leukotriene receptor antagonist; SR = slow-release
*Guidelines are the same for children ≤ 5 years (GINA) or < 5 years old (SIGN/BTS) unless specified.
† ICS doses are the beclometasone dipropionate equivalent doses.Thomas et al. BMC Pulmonary Medicine 2010, 10:29
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a recorded prescription for asthma controller therapy
(defined below) and who had no record of asthma con-
troller medication during the 6 months before date of the
prescription (index date). As further evidence of asthma
recorded in the database, children had to have either a
prior medical diagnosis of asthma; ≤ 2 episodes of wheez-
ing at least 28 days apart; or ≥ 2 prescriptions for a short-
acting β2 agonist (SABA) or ipratropium bromide at least
28 days apart. We excluded children with a history of
bronchopulmonary dysplasia, cystic fibrosis, or any
chronic pulmonary disorder other than asthma or wheez-
ing.
In addition, we randomly selected 792 children from
the full study cohort for inclusion in a physician-based
cross-sectional structured survey to assess asthma sever-
ity in relation to controller therapy. (A total of 900 chil-
dren were originally selected, and 108 of these were
ultimately excluded as these children had been prescribed
oral corticosteroids, not considered a controller therapy.)
Physicians were asked to complete the survey question-
naire (Additional file 1), retrospectively classifying
asthma severity at the index date and 6 months prior on
the basis of clinical data held electronically and other-
wise. Classification of asthma severity as per the Global
Initiative for Asthma (GINA) 2005 guidelines [9] was
provided to GPs to assist with the rating of severity. Com-
pleted surveys were returned to the GPRD and entered
into a dedicated database. Physicians were compensated
for completing the survey questionnaire.
Data extraction and analysis
We captured the following asthma controller therapies in
the database: ICS, inhaled LABA, ICS and LABA combi-
nations, sustained release β2-agonists, sustained release
theophylline, cromones, and antileukotrienes. We also
tabulated prescriptions for SABA on the index date, as
well as for 6 months before and 12 months after. Database
criteria for defining an asthma diagnosis and wheezing
are listed in Additional file 2.
We tabulated demographic characteristics, smoking
history, asthma duration, and the prescribed daily dose of
controller medication at the index date for each patient,
stratified by controller therapy type and, for the survey
cohort, asthma severity. In addition, we collected data on
respiratory and allergic comorbidities and on asthma-
related health care resource use for up to 24 months
before the index date.
Statistical methods
Descriptive statistics were used to characterise the distri-
bution of demographic factors, controller medication
prescribing at baseline, SABA prescriptions, comorbidi-
ties, and resource use. For categorical variables, the pro-
portion of patients with the variable(s) of interest was
calculated and compared using χ2  analysis or Fisher's
exact test. For quantitative variables, comparisons were
made using Student's t test, Wilcoxon rank-sum test, and
analysis of variance (ANOVA) where required. All statis-
tical analysis was conducted using STATA version 10
software (StataCorp LP, College Station, TX, USA).
Results
Full cohort and survey cohort-demographic and clinical 
characteristics at baseline (index date of controller therapy 
prescribing)
We identified 10,004 children 0-14 years old in the GPRD
who were prescribed asthma controller therapy between
September 1, 2006, and February 28, 2007, and who had
no controller prescription during the prior 6 months.
Their mean age was 8 years; 806 (8%) patients were 2
years or younger and the other patients were evenly dis-
tributed over the age range of 3-14 years; overall, 30%
were 5 years or younger; 59% were boys (T able 2). The
duration of asthma, as recorded in the GPRD, was ≤ 3
years for slightly over half of patients; 4-7 years for 28%,
and ≥ 8 years for 19%. Approximately half of children
were identified as having asthma because of a physician's
diagnosis in the database; approximately 40% were identi-
fied on the basis of SABA or ipratropium prescriptions;
and < 10% were identified because of a record of recur-
rent wheezing.
During the 6 months before the index date, 396 (4%)
children were prescribed an oral corticosteroid, and 525
(5%) received antibiotics for a lower respiratory tract
infection. Lung function test results, usually as peak expi-
ratory flow rate, were recorded during the 6 months pre-
ceding the index date for 974 (10%) children. On the
index date, lung function testing was performed for 1657
(17%) children, recorded as peak expiratory flow rate for
1581 (16%) children.
Of the 792 surveys sent to GPs, 635 (80%) were com-
pleted. The baseline characteristics of the surveyed
responder cohort were similar to those of the full cohort
(see Table 2) as well as to those of the survey nonre-
sponders (data not shown). Physicians completed the
asthma severity classification for all but 48 of 635 (8%)
patients: just over half (346/635, 55%) of patients were
reported as having intermittent asthma, and 159 (25%),
71 (11%), and 11 (2%) were reported as having mild, mod-
erate, and severe persistent asthma, respectively.
Full cohort and survey cohort-index therapy prescription 
patterns and doses of ICS monotherapy
Most children (91%) were prescribed ICS monotherapy
as asthma controller therapy (Table 2). Of those children
with defined dosing information, high doses of ICS (> 400
but ≤ 800 μg/day of chlorofluorocarbon (CFC)-beclom-
etasone or equivalent) were prescribed for 33/2140 (1.5%)Thomas et al. BMC Pulmonary Medicine 2010, 10:29
http://www.biomedcentral.com/1471-2466/10/29
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children < 5 years old and for 240/7452 (3.2%) children ≥5
years. The highest doses of ICS (> 800 μg/day of CFC-
beclometasone or equivalent) were prescribed for 11/
2140 (0.5%) < 5 years old and 180/7452 (2.4%) ≥ 5 years
old. (Doses of ICS were standardised to the CFC-beclom-
etasone dipropionate [CFC-BDP] equivalent dose using
the following ratios relative to CFC-BDP: budesonide
[BUD], fluticasone propionate [FP], BDP in solution
[QVAR®, Teva UK], and mometasone [MOM] at
BDP:BUD:FP:QVAR:MOM = 1:1:2:2:2, as per British
asthma guidelines [6,7].) Included among the "other"
therapy group, 45 (0.45%) children were prescribed
LABA as monotherapy.
For the surveyed responder cohort (those with known
asthma severity), monotherapy with ICS was prescribed
for all of the patients with severe asthma and approxi-
mately 90% of patients in the other severity classifications
(Figure 1). ICS and LABA either in fixed dose combina-
tion or in separate inhalers were prescribed to 8%, 9%,
and 10% of children with intermittent, mild, and moder-
ate asthma, respectively. Only five of the children with
reported asthma severity received an LTRA, adminis-
tered as monotherapy for four. Controller therapy pre-
scriptions and doses are summarised in Table 3.
Prescriptions for SABA were written for 31% of all
patients during the 6 months before their index controller
prescription; for 75% on the index date; and for 72% dur-
ing the 12 months after the index date. Similar overall
proportions of patients in the survey cohort as in the full
study cohort received SABA prescriptions, as shown in
Table 4. The proportions of patients receiving SABA pre-
scriptions varied significantly (P < 0.01) among controller
therapy groups, although no obvious pattern was evident,
Table 2: Characteristics of children new to asthma controller therapy, stratified by full cohort and survey responder cohort
Characteristic Full cohort (n = 10,004) Survey responders (n = 635) p value
Mean age (SD), yr 8.0 (3.8) 8.1 (3.8) 0.35
Age 0-2 yr, n (%) 806 (8.1%) 51 (8.0%)
Age 3-5 yr, n (%) 2155 (21.5%) 143 (22.5%)
Age 6-8 yr, n (%) 2307 (23.1%) 126 (19.8%)
Age 9-11 yr, n (%) 2402 (24.0%) 165 (26.0%)
Age 12-14 yr, n (%) 2334 (23.3%) 150 (23.6%)
Male sex, n (%) 5942 (59.4%) 365 (57.5%) 0.29
Smoking status 0.22
Non smoker 5651 (56.5%) 366 (57.6%)
Smoker 532 (5.3%) 31 (4.9%)
Ex smoker 77 (0.8%) 6 (0.9%)
Passive smoker 152 (1.5%) 3 (0.5%)
Unknown smoking status 3592 (35.9%) 229 (36.1%)
BMI, n 5816 393
Mean BMI (SD) 17.3 (5.3) 17.1 (5.0) 0.32
Median BMI (range) 16.6 (5.0-49.6) 16.7 (5.2-47.7) 0.75
Asthma duration: mean (SD), yr 4.3 (3.6) 4.4 (3.6) 0.56
Median (range), yr 3.7 (0.0-15.0) 3.9 (0.0-14.0) 0.62
Asthma controller therapy prescription at index date, n (%) 0.437
ICS monotherapy 9059 (90.6%) 575 (90.6%)
LABA in fixed dose combination 574 (5.7%) 43 (6.8%)
ICS + LABA 124 (1.2%) 4 (0.6%)
LTRA monotherapy 91 (0.9%) 6 (0.9%)
ICS + LTRA 55 (0.6%) 1 (0.2%)
Other 101 (1.0%) 6 (0.9%)
BMI = body mass index; ICS = inhaled corticosteroids; LABA = long-acting β2-agonists (in fixed dose combination is with ICS); LTRA = 
leukotriene receptor antagonists.Thomas et al. BMC Pulmonary Medicine 2010, 10:29
http://www.biomedcentral.com/1471-2466/10/29
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as well as among asthma severity groups excepting on the
index date (Table 4).
Full cohort-characteristics according to asthma controller 
therapy
Additional file 3 summarises baseline characteristics and
prior health care resource utilisation stratified according
to asthma controller therapy. We found significant differ-
ences among controller therapy groups for mean age, age
distribution, and asthma duration. Children who received
ICS and LABA either in fixed dose combination or in
separate inhalers tended to be older and to have a longer
duration of asthma than those in other treatment cohorts
(see Additional file 3). The prevalence of comorbidities
and health care resource utilisation before the index date
also differed significantly among controller therapy
groups.
Discussion
We found that the most common asthma controller ther-
apy recorded from September 2006 through February
2007 in the UK GPRD for children aged 14 years and
younger with no controller prescription during the prior
6 months was monotherapy with ICS, prescribed for over
90% of children. This is in line with UK guidelines [6,7].
However, the prescribing pattern for controller therapy in
the survey cohort did not vary much across asthma sever-
ity categories as classified by physicians. Monotherapy
with ICS, and beclometasone in particular, was the most
common prescription for children in each severity classi-
fication; mean daily doses of ICS did not change substan-
tially with asthma severity. Moreover, combination
therapy with ICS and LABA was prescribed in similar
proportions for patients with intermittent asthma (7.7%)
as for those with moderate asthma (9.9%).
Results of this observational study indicate that pre-
scribing practices did not always correspond to recom-
mendations of asthma management guidelines. Both
international and British asthma guidelines recommend
stepwise introduction of controller therapy, typically
beginning with low-dose ICS, defined in British guide-
lines as 200 μg/day of CFC-beclometasone dipropionate
or equivalent for children 12 years and younger and 400
μg/day for older children [6,7]. We found, instead, that
substantial numbers of children had no prescription for
ICS monotherapy during the prior 6 months and were
prescribed combination therapy with ICS and LABA or
doses of ICS as high as 800 μg/day. Of note, doses of >
800 μg/day are outside guideline and licensing parame-
ters, as are doses of > 400 μg/day for the younger age
group [7]. The high doses of ICS, recommended for use
only after careful thought in children with severe persis-
tent disease [7], were sometimes prescribed to children
c l a s s i f i e d  a s  h a v i n g  i n t e r m i t t e n t  o r  m i l d  p e r s i s t e n t
asthma.
The pattern of prescribing of combination therapy with
ICS and LABA, which asthma guidelines recommend for
patients with moderate or severe persistent asthma, was
Figure 1 Asthma controller therapy prescription, by asthma severity, for 635 children ≤ 14 years old. Children had not been prescribed an 
asthma controller medication in the prior 6 months. Data were derived from the UK General Practice Research Database. Asthma severity was defined 
by physicians according to GINA guidelines 2005 [9]. *Missing asthma severity classification. ICS = inhaled corticosteroid; LABA = long-acting β2-ag-
onist; LTRA = leukotriene receptor antagonist
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further evidence that recalled asthma severity and ther-
apy were not consistent. Combination ICS-LABA therapy
was prescribed for 7% of patients, most of whom were
classified as having intermittent or mild persistent
asthma; these children tended to be older and to have a
longer duration of asthma. Similarly, in a recent study of
insurance claims in the US [13], over half of children
(55%) receiving a first prescription for fluticasone propi-
onate and salmeterol in fixed-dose combination had no
record of pharmacy or medical claims during the prior
year that would appear to warrant ICS-LABA controller
therapy. In that study, as in the present study, a small per-
centage of children were prescribed LABA monotherapy,
which all guidelines strongly recommend against and
which lies outside the licence for this therapy class [6,8].
Recent studies have suggested that LABA use is
increasing in children, particularly as a first-line combi-
nation inhaler [14,15]. Although this may be appropriate
for some children [16,17], many could be managed with
ICS alone, and recent concerns have been expressed by
the US regulatory agency as to the increasing use of
LABAs in this age group, with the FDA tightening the
rules governing the use of this class of agents [18] and
leading experts calling for caution in their use [19].
Over 50% of patients in the survey cohort were classi-
fied as having intermittent asthma and thus, assuming
the classifications were correct, may not have asthma of
sufficient severity to warrant controller therapy. Both the
2005 GINA guidelines and the British asthma manage-
ment guidelines in effect at the time [7,9], as well as cur-
rent guidelines [6,8], recommend as-needed short-acting
bronchodilators as reliever therapy for intermittent
asthma; regular controller therapy is not initiated until
asthma symptoms become more regular or troublesome.
Guidelines recommend that patients on controller ther-
apy also have reliever bronchodilators available. We
found that approximately one third of patients had pre-
scriptions for SABA before the index date, and three
quarters received SABA prescriptions on the index date.
Table 3: Prescribed daily dose of controller medication at cohort entry by asthma severity--prescriptions with defined 
dosage information for survey cohort
Asthma severity classification
Intermittent (n = 346) Mild (n = 159) Moderate (n = 71) Severe (n = 11) Missing (n = 48)
Total no. prescriptions 351 164 75 13 51
Missing 7 (2.0%) 5 (3.0%) 1(1.3%) 0 3 (5.9%)
Beclometasone, no. 267 123 59 10 35
Mean dose (SD) 261 (126) 230 (112) 258 (107) 230 (95) 269 (149)
Budesonide, no. 33 11 4 2 3
Mean dose (SD) 218 (101) 364 (229) 350 (100) 300 (141) 400 (346)
F l u t i c a s o n e ,  n o . 1 9 8 311
Mean dose (SD) 216 (75) 150 (54) 167 (58) 100 200
Montelukast, no. 2 3 1 0 4
Mean dose (SD) 5 (0) 5 (1) 4 -- 5 (1)
Salmeterol, no. 4 1 1 0 1
Mean dose (SD) 88 (25) 50 100 -- 100
FDC Budesonide 1 3 1 0 3
Mean dose (SD) 1600 267 (116) 400 -- 333 (116)
FDC-Formoterol 1 3 1 0 3
Mean dose (SD) 48 16 (7) 24 -- 20 (7)
FDC-Fluticasone 3 10 5 0 16
Mean dose (SD) 400 (173) 180 (42) 240 (152) -- 294 (232)
FDC-Salmeterol 3 10 5 0 16
Mean dose (SD) 100 (0) 90 (21) 90 (22) -- 94 (25)
FDC = fixed-dose combination
Doses are actual doses as prescribed (μg/d).Thomas et al. BMC Pulmonary Medicine 2010, 10:29
http://www.biomedcentral.com/1471-2466/10/29
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Of the children with severe asthma, none were pre-
scribed additional therapy as add-on to ICS, although
almost half received oral corticosteroids on the index
date; these patients were too few in number (n = 11) to
enable us to draw conclusions from the findings. Leukot-
riene antagonists were not commonly prescribed. Finally,
objective measures of airway obstruction (spirometry or
peak flow measurement) were recorded for fewer than
one fifth of children.
Our findings point to sub-optimal clinical practice but
are not unusual. Clinical guidelines, including asthma
management guidelines, are often not followed in general
practice [20-23]. Other authors have found evidence of
off-label prescribing and high-dose ICS prescribing for
childhood asthma in the UK [14,24-27]. Many reasons
have been proposed for the failure to follow guidelines,
including incomplete dissemination, lack of agreement,
time pressures, inertia of prior practice, and, for the
youngest patients, lack of appropriate formulations [28].
In a recent Danish study, specialists were more likely than
GPs to provide guideline-adherent care to children with
asthma; nonetheless, overall, only one quarter of children
in the study received care in accordance with the guide-
lines [29].
Guidelines are formulated to present busy clinicians
with a summary of up-to-date evidence of the effective-
ness of different treatment options, and so to aid thera-
peutic decisions. The British asthma guidelines are
distributed to all clinicians treating asthma in the UK,
where this study occurred, and are accepted as the stan-
dard for asthma treatment. These guidelines recommend
that "...departures from the national guideline....should be
fully documented in the patient's case notes..." and justi-
fied [6,7]. Although it is recognized that following guide-
lines does not automatically lead to optimal outcomes,
studies show that outcomes can indeed be improved by
implementing recommendations from clinical practice
audits in line with guideline recommendations [30,31].
Moreover, guideline recommended management of acute
asthma is associated with improved outcomes [32].
Our findings describe prescribing practices specific to
the UK. Turner and coworkers [14] analysed longitudinal
trends in asthma therapies recorded in the GPRD from
1992-2004 for children 0-11 years old with an asthma
diagnosis: in 2004, approximately 9 of 10 children
received monotherapy with ICS and 1 in 10, add-on ther-
apy to ICS, most commonly LABA. Prior observational
studies, while different in design to the present study and
thus not directly comparable, depict quite different pre-
scribing patterns for childhood asthma controller therapy
in other countries. Relative to our findings for the UK, in
the US (1999-2000) montelukast was prescribed more
frequently [33]; in Taiwan (2002) ICS were prescribed less
frequently [34]; and in Norway (2004) combination ICS
plus LABA was prescribed more frequently [35].
The GPRD is a large, well-validated database that
records real-life prescribing practices and is relevant and
accepted for studying childhood asthma in the UK, as
most of these children are managed in primary care
[11,36,37]. Our findings, as for all database studies, are
Table 4: Short-acting β-agonist prescriptions
6 months prior On index date 12 months after
No. prescriptions, median (range) 1 (1-13) 1 (1-3) 2 (1-26)
Patients with prescriptions, by controller therapy, n (%)
ICS monotherapy (n = 9059) 2805 (31.0)* 6876 (75.9)* 6515 (71.9)*
ICS + LABA (n = 698) 174 (24.9) 497 (71.2) 519 (74.4)
ICS + LTRA (n = 55) 13 (23.6) 44 (80.0) 49 (89.1)
LTRA monotherapy (n = 91) 38 (41.8) 30 (33.0) 69 (75.8)
Other (n = 101) 31 (30.7) 62 (61.4) 82 (81.2)
Total (n = 10,004) 3061 (30.6) 7509 (75.1) 7234 (72.3)
Survey cohort: patients with prescriptions, by asthma severity, n (%)
Intermittent (n = 346) 87 (25.1)* 274 (79.2) 241 (69.7)*
Mild persistent (n = 159) 57 (35.9) 118 (74.2) 129 (81.1)
Moderate persistent (n = 71) 30 (42.3) 52 (73.2) 62 (87.3)
Severe persistent (n = 11) 6 (54.6) 9 (81.8) 9 (81.8)
Missing classification (n = 48) 13 (27.1) 31 (64.6) 36 (75.0)
Total (n = 635) 193 (30.4) 484 (76.2) 477 (75.1)
*P < 0.01 for comparisons among controller therapy groups or asthma severity groups.Thomas et al. BMC Pulmonary Medicine 2010, 10:29
http://www.biomedcentral.com/1471-2466/10/29
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dependent on the accuracy and completeness of record-
ing in the database [38]. Another study limitation is the
possibility that our database definitions incorrectly cate-
gorised children with regard to asthma diagnosis. More-
over, asthma in children under the age of 5 or 6 years is
difficult to diagnose and is essentially a provisional diag-
nosis, as wheezing often resolves with age [1,39]. Approx-
imately 30% of children in this study were aged 5 and
younger. Despite the difficulty in diagnosing asthma in
young children, we believe that observational research of
how wheezing children are treated in real-world practice
is important, as international and national guidelines
advise GPs on the ways to diagnose and manage asthma
in younger children, and GPs make the diagnosis on a fre-
quent basis. Wheezing illnesses are common in this age
group, and previous research has suggested that manage-
ment of these younger children in whom a clinical diag-
nosis of asthma has been made does not always
correspond to guideline recommendations [14,26].
An important study limitation is the possibility of miss-
ing data; for the survey sub-study we were unable to link
data on 51 prescriptions to asthma severity. Moreover, it
cannot be assumed that drugs as prescribed in the data-
base were also dispensed or consumed. In addition, our
findings could reflect seasonal trends, as we gathered
data for 6 months and not a full year. When available, we
gathered information on comorbid conditions for the
prior 24 months; however, some children did not have
data going back 24 months, e.g., those under 12 months
old, thus the patient percentages for these data may not
be comprehensive. Finally, asthma severity, based on
2005 GINA guidelines [9], was classified retrospectively
by physicians completing the survey; therefore, this tool
to guide clinicians in determining asthma severity was
not available to them at the time of prescribing and,
moreover, the results could have been biased by incom-
plete recall.
Conclusions
This cross-sectional study has enabled us to describe UK
primary care prescribing practices in late 2006 and early
2007 for asthma controller therapy for children with
recorded asthma or recurrent wheezing and no controller
therapy in the prior 6 months. We found that physician
classifications of asthma severity did not always corre-
spond to guideline recommendations for prescribing
controller therapy. Children classified as having intermit-
tent asthma were prescribed controller therapy with ICS,
sometimes at high doses, and those with intermittent and
mild asthma received combination therapy with ICS and
LABA. High doses of ICS were prescribed without a prior
low-dose ICS prescription for some children, and combi-
nation therapy with ICS and LTRA was rarely prescribed.
In UK primary care, despite endorsement in local guide-
l i n e s ,  c h i l d r e n  w i t h  a s t h m a  a r e  s e l d o m  t r e a t e d  w i t h
LTRA, and monotherapy with ICS is the most common
controller therapy at all levels of severity.
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